Background The aim of this study is to describe the frequency and management of low-level viremia (LLV, i.e. HIV RNA >50 but <200 copies/mL) at the beginning and in course of long-acting (LA) injectable cabotegravir (CAB) and rilpivirine (RPV).
LOW LEVEL VIREMIA AT THE BEGINNING AND IN COURSE OF LONG-ACTING TREATMENT WITH INJECTABLE CABOTEGRAVIR AND RILPIVIRINE
GF Pellicanò;
2024-01-01
Abstract
Background The aim of this study is to describe the frequency and management of low-level viremia (LLV, i.e. HIV RNA >50 but <200 copies/mL) at the beginning and in course of long-acting (LA) injectable cabotegravir (CAB) and rilpivirine (RPV).File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
